Episode Details

Dry macular degeneration is the leading cause of blindness in Australian adults. New treatments including non-invasive microcurrent pulse therapy and injections are showing promising results in slowing vision loss, though the injections may soon cost patients around $18,000 annually after the producer withdrew its application for the Pharmaceutical Benefits Scheme. Researchers continue to evaluate the efficacy and accessibility of these emerging treatment options.

See omnystudio.com/listener for privacy information.